Why the study?
The registry was designed to prospectively assess the population, indications, and outcomes using second-generation phased RF ablation (pulmonary vein ablation catheter GOLD) in real-world standard-of-care use for paroxysmal and persistent AF.
Does second-generation phased radiofrequency ablation prevent AF recurrence and improve quality of life in patients with paroxysmal and persistent atrial fibrillation?
Does second-generation phased radiofrequency ablation prevent AF recurrence and improve quality of life in patients with paroxysmal and persistent atrial fibrillation?
Phased RF ablation using the PVAC GOLD catheter provides 77.7% freedom from AF recurrence at 12 months with low complication rates and significant improvements in quality of life.
No takes yet. Share an insight, caveat, or question.
Phased RF ablation was associated with 78% 12-month freedom from recurrence and low complications in real-world AF; leaves open comparative effectiveness versus other strategies.
Boersma et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: